- Regulatory Support: The FDA strongly encourages genomic sampling to maximize the value of clinical data and optimize patient therapy.
- Precision Recruitment: Genetic profiling allows for patient stratification, ensuring candidates are more likely to respond to specific treatments.
- Reduced Costs: Identifying ineffective therapies early through genomics speeds up trials and lowers overall R&D expenses.
- Enhanced Engagement: Genomics-based trials often provide higher levels of patient support and expert guidance, leading to better retention.
- Future of Medicine: Large-scale genomic data is the foundation for transitioning toward truly personalized healthcare.
How genomics improves clinical trial design and execution
The FDA has made its position clear. Its guidance for E18 Genomic Sampling and Management of Genomic Data states:
"With advances in science and increased awareness of the impact of genomics, there is a need and an opportunity to maximize the value of the collected samples and the data generated from them. Therefore, genomic sample acquisition is strongly encouraged in all phases and studies of clinical development."
This is not a future aspiration. Clinical programs that incorporate genetic testing are already demonstrating improvements in patient selection, trial efficiency, and long-term data value. The sections below outline the primary ways genomics contributes to trial success, drawing on published research and operational evidence.
Identifying sources of variability
A primary reason clinical trials incorporate genomics is to account for variability in treatment response. Patients may share a diagnosis but differ significantly at the molecular level. Genomic sequencing enables researchers to identify the specific genetic variants that influence how individuals respond to a given therapy.
This process drives the identification of biomarkers associated with clinical outcomes. Biomarkers play a critical role in drug development. As the FDA states, 'the identification of genomic biomarkers underlying variability in drug response may be valuable to optimize patient therapy, design more efficient studies, and inform drug labeling.'
In practice, this means sponsors can use genomic data to refine inclusion and exclusion criteria, stratify patient populations more precisely, and design trials that are better powered to detect a true treatment effect.
Finding the right patients
By utilizing genomics at the point of recruitment, these underlying genetic differences can be used to distinguish patients into subgroups. This stratification is what determines whether sponsors are recruiting from a genetically qualified population or simply a diagnosed one, a distinction that has direct consequences for screen failure rates and cohort integrity.
According to research by KPMG, using genetic profiles allows R&D teams to:
- Narrow down patient groups into high-response subsets.
- Speed up the duration of clinical trials.
- Eliminate ineffective therapies at an earlier stage.
- Get products to market sooner and at a lower cost.
Payer pressure to demonstrate clinical utility in defined patient subgroups is increasingly shaping reimbursement expectations, making genetic stratification relevant not only to trial design but to the commercial viability of the asset.
Driving outreach and awareness
While the implementation of genomics may advance our understanding of diseases and improve drug efficacy, in some studies, the patient identification process may become much longer, particularly in the case of rare diseases. Research on executing successful clinical trials by David B. Fogel highlights this challenge. Fogel states that “bringing eligibility to the level of the individual holds the promise for establishing greater study drug efficacy but also has the drawback of limiting the available sample size.
To find adequate numbers more quickly, clinical researchers can consider building partnerships with global genomic research platforms. Partnerships and collaborative initiatives can help researchers raise awareness, gain broader reach and increase the pool of potential participants to enable faster trials. For example, these techniques were implemented to drive patient engagement in Alzheimer’s disease research.
To increase the pool of potential participants, Fundació ACE recommends several key strategies:
- Site Expansion: Increasing the number of recruiting locations.
- Registry Coordination: Better management of participant databases.
- Local Integration: Coordinating with primary care and local medical centers.
- Public Awareness: Improving attitudes toward research through targeted advertisement and outreach.
Increasing patient engagement
A critical part of genomics-based trials involves interpreting genetic test results and providing ongoing support to participants. This requires collaboration with genetic counselors, specialized physicians, and genomics testing platforms that deliver detailed and reliable patient insights. Telemedicine extends this support to patients regardless of geographic location, which is particularly important in multi-country or rare disease studies.
This high-touch approach increases patient involvement across all phases of the trial. When participants feel informed and supported, they are more likely to remain engaged throughout the study, complete required assessments, and respond to follow-up communications.
The downstream impact is significant. Higher engagement during a trial creates a foundation for recontact in future studies and pharmacovigilance programs. Rather than rebuilding patient relationships from scratch for each new program, sponsors can maintain a continuous connection that compounds in value over time.
Navigating the global regulatory landscape
As genomics becomes standard in trial design, sponsors must account for regulatory variation across geographies. Requirements for genomic sample collection, consent, data handling, and reporting differ between the US, Europe, and other regions. The WHO's Global Observatory on Health Research and Development actively monitors human genomics technologies in clinical trials, reflecting the growing global attention to how these tools are governed and deployed.
For multi-country programs, this means genomic workflows must be designed with regulatory and compliance considerations built in from the start, not layered on after the study is underway. Sponsors who plan for cross-border variability in genomic data requirements are better positioned to execute consistently across sites and avoid delays tied to country-specific compliance gaps.
Advancing personalized medicine through genomic data
Widespread adoption of genomics within clinical trials is necessary to generate the scale of genetic data, repeatable outcomes, and longitudinal evidence required to advance personalized medicine. Each trial that collects and manages genomic sequencing data contributes to a growing body of knowledge that informs future trial design, biomarker discovery, and therapeutic targeting.
As more trials integrate genetic testing, the data generated across programs creates a compounding asset. Sponsors who manage this data within compliant, recontactable frameworks can draw on it across the full research lifecycle, from early feasibility through post-market follow-up.
As more programs are designed around genetic eligibility, the decisions made at protocol design, patient identification, and testing integration stages will increasingly determine whether a trial reaches enrollment targets or stalls before it starts.